EMA Withdrawn: Natpar (parathyroid hormone) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

EU EMA has withdrawn Natpar (parathyroid hormone) by Takeda; therapeutic area hypoparathyroidism with previous conditional and orphan designations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• Natpar (parathyroid hormone)

Snippet

Status: Withdrawn. Therapeutic area: Hypoparathyroidism. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 11/07/2025. Conditional approval. Orphan medicine